Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
CRYPTO
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
TECHNOLOGY
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
STOCKS
Will Gilead Sciences Stock Really Rally 33% From Here?
By Bret Kenwell
Jul 15, 2019 3:29 PM EDT
PRESS RELEASES
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Galapagos NV - GLPG
By PR Newswire
Mar 3, 2021 3:20 AM EST
PRESS RELEASES
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Galapagos NV - GLPG
By PR Newswire
Feb 19, 2021 1:05 AM EST
PRESS RELEASES
Galapagos And Gilead Discontinue ISABELA Phase 3 Trials In IPF
By Business Wire
Feb 10, 2021 9:00 AM EST
PRESS RELEASES
Selvita Completes Acquisition Of Fidelta From Galapagos
By PR Newswire
Jan 4, 2021 4:05 PM EST
PRESS RELEASES
Gilead And Galapagos Announce New Commercialization And Development Agreement For Jyseleca® (Filgotinib)
By Business Wire
Dec 15, 2020 4:15 PM EST
PRESS RELEASES
Selvita To Acquire Fidelta From Galapagos
By PR Newswire
Nov 23, 2020 4:15 PM EST
PRESS RELEASES
European Medicines Agency Validates Marketing Application For Filgotinib For The Treatment Of Ulcerative Colitis
By Business Wire
Nov 2, 2020 4:01 PM EST
PRESS RELEASES
Phase 2b/3 Trial Shows Efficacy Of Filgotinib For The Induction And Maintenance Of Remission In Moderately And Severely Active Ulcerative Colitis
By Business Wire
Oct 12, 2020 9:15 AM EDT
PRESS RELEASES
European Commission Grants Marketing Authorization For Jyseleca® ▼ (Filgotinib) For The Treatment Of Adults With Moderate To Severe Active Rheumatoid Arthritis
By Business Wire
Sep 25, 2020 1:00 PM EDT
PRESS RELEASES
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Galapagos NV - GLPG
By PR Newswire
Aug 19, 2020 8:01 PM EDT
PRESS RELEASES
Gilead And Galapagos Announce Positive European CHMP Opinion For Jyseleca® (Filgotinib) For The Treatment Of Adults With Moderate To Severe Rheumatoid Arthritis
By Business Wire
Jul 24, 2020 8:10 AM EDT
PRESS RELEASES
New Analyses Of Phase 2 EQUATOR Clinical Program Support Durable Efficacy Of Filgotinib In Psoriatic Arthritis
By Business Wire
Jun 5, 2020 4:01 PM EDT
PRESS RELEASES
Gilead And Galapagos Announce Positive Topline Results Of Phase 2b/3 Trial Of Filgotinib In Moderately To Severely Active Ulcerative Colitis
By Business Wire
May 20, 2020 4:03 PM EDT
PRESS RELEASES
Galapagos And Ryvu Announce Research Collaboration
By PR Newswire
Apr 16, 2020 2:12 AM EDT
STOCKS
Will Gilead Sciences Stock Really Rally 33% From Here?
By Bret Kenwell
Jul 15, 2019 3:29 PM EDT
STOCKS
Gilead Boosts Investment in Inflammatory Specialist Galapagos by $5.1 Billion
By Martin Baccardax
Jul 15, 2019 9:40 AM EDT
STOCKS
Galapagos Soars After Rheumatoid Arthritis Drug Meets Primary Endpoint
By Alexander Nicoll
Mar 29, 2019 11:06 AM EDT
STOCKS
Vertex Pharma jumps 14% after rival releases poor cystic fibrosis drug results
By Alexander Nicoll
Jun 29, 2018 3:27 PM EDT
STOCKS
Vertex pharma moves next-generation cystic fibrosis drugs into new clinical trials
By Adam Feuerstein
Oct 25, 2016 5:03 PM EDT
STOCKS
Celgene skips the placebo, fails drug development 101
By Adam Feuerstein
Oct 19, 2016 7:28 AM EDT
STOCKS
AstraZeneca, Gilead Drug License Deals Could Pinch AbbVie Growth
By Adam Feuerstein
Dec 17, 2015 8:48 AM EST
STOCKS
Vertex to Test New Cystic Fibrosis Drugs, Seeking Broader, More Effective Treatments
By Adam Feuerstein
Oct 8, 2015 12:10 PM EDT
STOCKS
Credit Suisse's 8 Pharmaceutical Stocks With 'Significant' Upside
By Laurie Kulikowski
Aug 28, 2015 12:58 PM EDT
STOCKS
Galapagos Receives a Rousing Welcome on Its First Day of Trading
By James Rubin
May 14, 2015 6:27 PM EDT
